Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia

Wenbing Liu, Yu Liu, Anli Lai, Runxia Gu, Ying Wang, Qing Rao, Yingchang Mi, Hui Wei, Shaowei Qiu, Min Wang, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 2927.

https://doi.org/10.1182/blood-2024-198599

Published: 2024

Journal Articles

Overexpression of GAD1 in Pediatric Acute Myeloid Leukemia Cells Impairs Cytotoxic T Lymphocyte Response to Tumor Cells

Xiaoxiao Chen, Bowen Cui, Shuang Zhao, Kefei Wu, Yangyang Xie, Hui Liu, Jiaoyang Cai, Xiang Wang, Yixiao Mo, Wenting Hu, Changcheng Chen, Han Wang, Ronghua Wang, Huiying Sun, Jianan Rao, Wenyan Wu, Yu Liu, Shuhong Shen

Blood (2024) 144 (Supplement 1): 4319.

https://doi.org/10.1182/blood-2024-206639

Published: 2024

Journal Articles

CRISPR-Cas9 Screening Identifies Therapeutic Targets for AML1-ETO Positive Leukemia

Chengcai Guo, Yu Liu, Qing Rao, Runxia Gu, Shaowei Qiu, Min Wang, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 2734.

https://doi.org/10.1182/blood-2024-194291

Published: 2024

Journal Articles

Identification of Megakaryocytes As a Functional Component of Circulation Blood

Ying Lei, Jia Si, Yu Liu, Pucai Xia, Yukuan Liu, Jie Zhang, Xiaohui Zhang, Yueying Li, Qian-Fei Wang

Blood (2024) 144 (Supplement 1): 3927.

https://doi.org/10.1182/blood-2024-209348

Published: 2024

Journal Articles

ADGRG1/GPR56 As a Marker of CD8 + Tumor-Reactive T Cells in Acute Myeloid Leukemia

Yihan Mei, Yu Liu, Wenbing Liu, Manling Chen, Qing Rao, Min Wang, Shaowei Qiu, Runxia Gu, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 4289.

https://doi.org/10.1182/blood-2024-194281

Published: 2024

Journal Articles

Higher NOTCH1 Mutation Load Reveals Favorable Prognosis in Pediatric T-Cell Acute Lymphoblastic Leukemia

Senlin Zhang, Qi Ji, Zhiqi Zhang, Ping Chen, Xinran Chu, Na Meng, Xiao Zhang, Wei Gao, Minyuan Liu, Yu Liu, Shaoyan Hu

Blood (2024) 144 (Supplement 1): 5927.

https://doi.org/10.1182/blood-2024-210747

Published: 2024

Journal Articles

Orelabrutinib-Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Treatment of Marginal Zone Lymphoma: A Retrospective Study

He LI, Jiazhuo Liu, Yuhui Chen, Pazilaiti Tuohuti, Yutong Wang, Xinzhu Tang, Bing Xiang, Yongqian Jia, Yu Wu, Yun Tang, Yong Guo, Jie Wang, Yuhuan Zheng, Yu Liu, Ting Niu

Blood (2024) 144 (Supplement 1): 6308.

https://doi.org/10.1182/blood-2024-206464

Published: 2024

Journal Articles

Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia

Yu Liu, Wenbing Liu, Yihan Mei, Qing Rao, Runxia Gu, Min Wang, Jianxiang Wang, Shaowei Qiu

Blood (2024) 144 (Supplement 1): 328.

https://doi.org/10.1182/blood-2024-194287

Published: 2024

Journal Articles

Azacytidine Plus PD-1 Therapy in Relapsed or Refractory Hodgkin Lymphoma

Liren Qian, Haiyan Zhu, Yu Liu, Mingshuang Ding, Horia Bumbea, Ciprian Tomuleasa

Blood (2024) 144 (Supplement 1): 6379.

https://doi.org/10.1182/blood-2024-193163

Published: 2024

Journal Articles

SLC25A21 Correlates with the Prognosis of Adult Acute Myeloid Leukemia through Inhibiting the Growth of Leukemia Cells Via Downregulating CXCL8

Shujuan Wang, Yu Liu, Yan Xu, Qianqian Hao, Luyao Shi, Yufei Chen, Yajun Liu, Mengya Li, Yu Zhang, Tao Li, Yafei Li, Zhongxing Jiang, Yanfang Liu, Chong Wang, Bian Zhilei, Lu Yang, Wenyi Lu

Blood (2024) 144 (Supplement 1): 6133.

https://doi.org/10.1182/blood-2024-199630

Published: 2024

Journal Articles

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 623.

https://doi.org/10.1182/blood-2023-179160

Published: 2023

Journal Articles

Comparing Phenotyping, Gene Expression, and Function of T Lymphocytes before Mobilization Chemotherapy Versus after Stem Cell Harvesting in Patients with B Cell Lymphoma and Multiple Myeloma

Sheng-Hsuan Chien, Xiuli Wang, Wen-Chun Chen, Chun-Yu Liu

Blood (2023) 142 (Supplement 1): 2147.

https://doi.org/10.1182/blood-2023-173443

Published: 2023

Journal Articles

Preclinical Study of DZD8586, a Non-Covalent LYN/BTK Dual Inhibitor with Excellent BBB Penetration, for the Treatment of B-Cell Non-Hodgkin Lymphoma (B-NHL)

Yu Bai, Ting Wu, Minghui Hu, Sufang Han, Yu Liu, Jie Zheng, Junjun Qin, Lin Zhang, Zhenfan Yang

Blood (2023) 142 (Supplement 1): 2822.

https://doi.org/10.1182/blood-2023-185156

Published: 2023

Journal Articles

AML1-ETO and CCND2 Overexpression Cooperate to Drive AML Initiation and Progression

Junli Mou, Yu Liu, Xiaoyu Liu, Runxia Gu, Yingxi Xu, Kejing Tang, Zheng Tian, Haiyan Xing, Qing Rao, Min Wang, Shaowei Qiu, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 4129.

https://doi.org/10.1182/blood-2023-179869

Published: 2023

Journal Articles

CRISPR-Cas9 Screening Identifies Therapeutic Targets for AML1-ETO Positive Leukemia

Chengcai Guo, Yu Liu, Qing Rao, Shaowei Qiu, Runxia Gu, Min Wang, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 5697.

https://doi.org/10.1182/blood-2023-179262

Published: 2023

Journal Articles

Modulation of Biomarkers By BET Inhibitor, BMS-986158, Including JAK2 Variant Allele Frequency (VAF), Bone Marrow (BM) Fibrosis, and Reversal of Abnormal Cytokine Production in Intermediate- or High-Risk Myelofibrosis (MF)

Si Tuen Lee-Hoeflich, Christopher Brueckner, Lawrence Litalien, Ke Xu, Sharmila Das, Laura Corella, Sherif Daouti, Oriana Esposito, Emma Lees, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, Bin Wu

Blood (2023) 142 (Supplement 1): 3158.

https://doi.org/10.1182/blood-2023-181620

Published: 2023

Journal Articles

IKZF2 Specifically Participates in AML1-ETO Mediated Blockage of Myeloid Differentiation

Yu Liu, Chengcai Guo, Wenbing Liu, Xiaoyu Liu, Qing Rao, Runxia Gu, Shaowei Qiu, Min Wang, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2023-179854

Published: 2023

Journal Articles

Genomic Landscape of Pediatric Non-Down's Syndrome Acute Megakaryoblastic Leukemia in China

Blood (2023) 142 (Supplement 1): 4331.

https://doi.org/10.1182/blood-2023-181798

Published: 2023

Journal Articles

Thrombosis Caused By a Novel Coagulation Factor IX Mutation (FIX Shanghai II)

Wenman WU, Rui Wang, Qin Xu, Guanzheng Wang, Shifeng Jiang, Can Lou, Xi Wu, Yanyan Shao, Yeling Lu, Yu Liu, Guanquan Xu, Qiulan Ding, Xiaobo Hu, Xuefeng Wang, Jing Dai

Blood (2023) 142 (Supplement 1): 1233.

https://doi.org/10.1182/blood-2023-184596

Published: 2023

Journal Articles

Prognostic Features of CD9 in Childhood Acute Lymphoblastic Leukemia - a Retrospective Analysis of a Nation-Wide Multicenter Study in China

Kathy Yuen Yee Chan, Jiaoyang Cai, Yu Liu, Jun J. Yang, Ching-Hon Pui, Shuhong Shen, Chi Kong Li, Kam Tong Leung

Blood (2023) 142 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2023-191098

Published: 2023

NARROW

The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia

Overexpression of GAD1 in Pediatric Acute Myeloid Leukemia Cells Impairs Cytotoxic T Lymphocyte Response to Tumor Cells

CRISPR-Cas9 Screening Identifies Therapeutic Targets for AML1-ETO Positive Leukemia

Identification of Megakaryocytes As a Functional Component of Circulation Blood

ADGRG1/GPR56 As a Marker of CD8 + Tumor-Reactive T Cells in Acute Myeloid Leukemia

Higher NOTCH1 Mutation Load Reveals Favorable Prognosis in Pediatric T-Cell Acute Lymphoblastic Leukemia

Orelabrutinib-Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Treatment of Marginal Zone Lymphoma: A Retrospective Study

Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia

Azacytidine Plus PD-1 Therapy in Relapsed or Refractory Hodgkin Lymphoma

SLC25A21 Correlates with the Prognosis of Adult Acute Myeloid Leukemia through Inhibiting the Growth of Leukemia Cells Via Downregulating CXCL8

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Comparing Phenotyping, Gene Expression, and Function of T Lymphocytes before Mobilization Chemotherapy Versus after Stem Cell Harvesting in Patients with B Cell Lymphoma and Multiple Myeloma

Preclinical Study of DZD8586, a Non-Covalent LYN/BTK Dual Inhibitor with Excellent BBB Penetration, for the Treatment of B-Cell Non-Hodgkin Lymphoma (B-NHL)

AML1-ETO and CCND2 Overexpression Cooperate to Drive AML Initiation and Progression

CRISPR-Cas9 Screening Identifies Therapeutic Targets for AML1-ETO Positive Leukemia

Modulation of Biomarkers By BET Inhibitor, BMS-986158, Including JAK2 Variant Allele Frequency (VAF), Bone Marrow (BM) Fibrosis, and Reversal of Abnormal Cytokine Production in Intermediate- or High-Risk Myelofibrosis (MF)

IKZF2 Specifically Participates in AML1-ETO Mediated Blockage of Myeloid Differentiation

Genomic Landscape of Pediatric Non-Down's Syndrome Acute Megakaryoblastic Leukemia in China

Thrombosis Caused By a Novel Coagulation Factor IX Mutation (FIX Shanghai II)

Prognostic Features of CD9 in Childhood Acute Lymphoblastic Leukemia - a Retrospective Analysis of a Nation-Wide Multicenter Study in China

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only